These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 19349352)

  • 1. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
    Kuo KT; Mao TL; Jones S; Veras E; Ayhan A; Wang TL; Glas R; Slamon D; Velculescu VE; Kuman RJ; Shih IeM
    Am J Pathol; 2009 May; 174(5):1597-601. PubMed ID: 19349352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
    Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
    Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
    Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
    Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
    Prat J; D'Angelo E; Espinosa I
    Hum Pathol; 2018 Oct; 80():11-27. PubMed ID: 29944973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
    Kato N; Sato Y; Kamataki A; Fukase M; Uchigasaki S; Kurose A
    Hum Pathol; 2019 Apr; 86():32-37. PubMed ID: 30496799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
    Lee S; Garner EI; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2007 Aug; 106(2):311-7. PubMed ID: 17532031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.
    Stemke-Hale K; Shipman K; Kitsou-Mylona I; de Castro DG; Hird V; Brown R; Flanagan J; Gabra H; Mills GB; Agarwal R; El-Bahrawy M
    Mod Pathol; 2013 Apr; 26(4):544-52. PubMed ID: 23174937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas.
    Gyftaki R; Liacos C; Politi E; Liontos M; Saltiki K; Papageorgiou T; Thomakos N; Haidopoulos D; Rodolakis A; Alevizaki M; Bamias A; Dimopoulos A
    Int J Gynecol Cancer; 2014 Jun; 24(5):851-6. PubMed ID: 24844218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
    Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
    J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
    Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
    Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.
    Kuo KT; Mao TL; Chen X; Feng Y; Nakayama K; Wang Y; Glas R; Ma MJ; Kurman RJ; Shih IeM; Wang TL
    Clin Cancer Res; 2010 Apr; 16(7):1997-2008. PubMed ID: 20233889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
    Uehara Y; Oda K; Ikeda Y; Koso T; Tsuji S; Yamamoto S; Asada K; Sone K; Kurikawa R; Makii C; Hagiwara O; Tanikawa M; Maeda D; Hasegawa K; Nakagawa S; Wada-Hiraike O; Kawana K; Fukayama M; Fujiwara K; Yano T; Osuga Y; Fujii T; Aburatani H
    PLoS One; 2015; 10(6):e0128066. PubMed ID: 26043110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
    Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
    Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
    Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.